Unrecognized and Unappreciated Secondary Causes of Osteoporosis

Endocrinology and Metabolism Clinics of North America

Volumn 41, Issue 3, 2012, Pages 613-628

  Miller, Paul D ^a  

^a Health Sciences Center and Colorado Center for Bone Research   (United States)

Author keywords

Bone; Cause; Secondary osteoporosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANASTROZOLE; ANTICONVULSIVE AGENT; AROMATASE INHIBITOR; CALCINEURIN INHIBITOR; CYCLOSPORIN; DENOSUMAB; GLUCOCORTICOID; GONADORELIN AGONIST; HEPARIN; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; PROTON PUMP INHIBITOR; RISEDRONIC ACID; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; ZOLEDRONIC ACID;

BARIATRIC SURGERY; BONE DENSITY; BONE FRAGILITY; BREAST CANCER; CAUSAL ATTRIBUTION; CELIAC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CROHN DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EATING DISORDER; FRACTURE; HUMAN; HYPERCALCIURIA; HYPERTHYROIDISM; KIDNEY DYSFUNCTION; KIDNEY TUBULE ACIDOSIS; MASTOCYTOSIS; MONOCLONAL IMMUNOGLOBULINEMIA; OSTEOLYSIS; OSTEOPOROSIS; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ACIDOSIS, RENAL TUBULAR; AROMATASE INHIBITORS; BONE AND BONES; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; DIABETES COMPLICATIONS; EATING DISORDERS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MEDROXYPROGESTERONE ACETATE; OSTEOPOROSIS; PROTON PUMP INHIBITORS;

EID: 84864812296     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2012.05.005     Document Type: Review

References (97)

1. Krieger N.S., Frick K.K., Bushinsky D.A. Mechanism of acid-induced bone resorption. Curr Opin Nephrol Hypertens 2004, 13(4):423-436.
2. Lemann J., Bushinsky D.A., Hamm L.L. Bone buffering of acid and base in humans. Am J Physiol Renal Physiol 2003, 285(5):F811-F832. Review.
3. Grieff M., Bushinsky D.A. Diuretics and disorders of calcium homeostasis. Semin Nephrol 2011, 31(6):535-541. Review.
4. Painter S.E., Kleerekoper M., Camacho P.M. Secondary osteoporosis: a review of the recent evidence. Endocr Pract 2006, 12:436-445.
5. Miazgowski T., Kleerekoper M., Felsenberg D., et al. Secondary osteoporosis: endocrine and metabolic causes of bone mass deterioration. J Osteoporos 2012, 2012:907214.
6. Bogoch E.R., Elliot-Gibson V., Wang R.Y., et al. Secondary causes of osteoporosis in fracture patients. J Orthop Trauma 2012, [Epub ahead of print].
7. Osteoporosis prevention, diagnosis and therapy. NIH Consens Statement 2000, 17(1):1-45. Review.
8. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994, 843:1-129.
9. Miller P.D., Bonnick S.L., Rosen C.J. Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population. Calcif Tissue Int 1996, 58:207-214.
10. Miller P.D., Zapalowski C., Kulak C.A., et al. Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab 1999, 84:1867-1871.
11. Adler R.A. Laboratory testing for secondary osteoporosis evaluation. Clin Biochem 2012, [Epub ahead of print].
12. Tannenbaum C., Clark J., Schwartzman K., et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2003, 87:4431-4437.
13. Lewiecki E.M., Bilezikian J.P., Khosla S., et al. Osteoporosis update from the 2010 Santa Fe Bone Symposium. J Clin Densitom 2011, 14(1):1-21.
14. Worcester E.M., Coe F.L. Clinical practice. Calcium kidney stones. N Engl J Med 2010, 363(10):954-963.
15. Consensus conference Prevention and treatment of kidney stones. J Am Med Assoc 1988, 260(7):977-981.
16. Asplin J.R., Bauer K.A., Kinder J., et al. Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int 2003, 63(2):662-669.
17. Pietschmann F., Breslau N.A., Pak C.Y.C. Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 1992, 7:1383-1388.
18. Jaeger P., Lippuner K., Casez J.P., et al. Low bone mass in idiopathic renal stone formers: magnitude and significance. J Bone Miner Res 1994, 9(10):1525-1532.
19. Giannini S., Nobile M., Sartori L., et al. Bone density and skeletal metabolism are altered in idiopathic hypercalciuria. Clin Nephrol 1998, 50(2):94-100.
20. Da Silva A.M.M., Dos Reis L.M., Pereira R.C., et al. Bone involvement in idiopathic hypercalciuria. Clin Nephrol 2002, 57(3):183-191.
21. Tasca A., Cacciola A., Ferrarese P., et al. Bone alterations in patients with idiopathic hypercalciuria and calcium nephrolithiasis. Urology 2002, 59(6):865-869.
22. Pak C.Y., Kaplan R., Bone H., et al. A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. N Engl J Med 1975, 292(10):497-500.
23. Bushinsky D.A. Acidosis and bone. Miner Electrolyte Metab 1994, 20(1-2):40-52. Review.
24. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
25. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009, 76(Suppl 113):S1-S130. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group.
26. Jamal S., West S., Miller P.D. Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int 2012, 23(4):1191-1198.
27. Miller P.D. Fragility fractures in chronic kidney disease: an opinion-based approach. Cleve Clin J Med 2009, 76:715-723.
28. Miller P.D. The kidney and bisphosphonates. Bone 2011, 49(1):77-81.
29. Bida J.P., Kyle R.A., Therneau T.M., et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc 2009, 84(8):685-693.
30. Jagannath S. Value of serum free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology. Clin Lymphoma Myeloma 2007, 7(8):518-523.
31. Varettoni M., Corso A., Cocito F., et al. Changing pattern of presentation of monoclonal gammopathy of undetermined significance: a single-center experience with 1,400 patients. Medicine (Baltimore) 2010, 89(4):211-216.
32. Tian E., Zhan F., Walker R., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349(26):2483-2494.
33. Barete S., Assous N., de Gennes C., et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010, 69:1838-1841.
34. Valent P., Akin C., Escribano L., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37:435-453.
35. Lidor C., Frisch B., Gazit D., et al. Osteoporosis as the sole presentation of bone marrow mastocytosis. J Bone Miner Res 1990, 5:871-876.
36. De Gennes C., Kuntz D., de Vernejoul M.C. Bone mastocytosis: a report of nine cases with a bone histomorphometric study. Clin Orthop Relat Res 1992, 279:281-291.
37. Brumsen C., Papapoulos S.E., Lentjes E.G., et al. A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men. Bone 1990, 31:556-561.
38. Oranje A.P., Mulder P.G., Heide R., et al. Urinary N-methyl histamine as an indicator of bone marrow involvement in mastocytosis. Clin Exp Dermatol 2002, 27:502-506.
39. van der Windt D.A., Jellema P., Mulder C.J., et al. Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review. JAMA 2010, 303(17):1738-1746.
40. Moschen A.R., Kaser A., Enrich B., et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005, 54:479-487.
41. Compston J. Osteoporosis in inflammatory bowel disease. Gut 2003, 52:63-64.
42. van Hogezand R.A., Banffer D., Zwinderman A.H., et al. Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease. Osteoporos Int 2006, 17:535-542.
43. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303(3):235-241.
44. Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health 2007, 121(7):492-496.
45. Mechanick J.I., Kushner R.F., Sugerman H.J., et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Endocr Pract 2008, 14(Suppl 1):1-83.
46. Shapses S.A., Cifuentes M. Body weight/composition and weight change: effects on bone health. Nutrition and bone health 2004, 549-573. Humana Press, New Jersey. M.F. Holick, B. Dawson-Hughes (Eds.).
47. Shapses S.A., Riedt C.S. Bone, body weight, and weight reduction: what are the concerns?. J Nutr 2006, 136:1453-1456.
48. Coates P.S., Fernstrom J.D., Fernstrom M.H., et al. Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab 2004, 89(3):1061-1065.
49. Pugnale N., Giusti V., Suter M., et al. Bone metabolism and risk of secondary hyperparathyroidism 12 months after gastric banding in obese pre menopausal women. Int J Obes Relat Metab Disord 2003, 27(1):110-116.
50. Haria D.M., Sibonga J.D., Taylor H.C. Hypocalcemia, hypovitaminosis D osteopathy, osteopenia, and secondary hyperparathyroidism 32 years after jejunoileal bypass. Endocr Pract 2005, 11:335-340.
51. Bal B.S., Finelli F.C., Shope T.R., et al. Nutritional deficiencies after bariatric surgery. Nat Rev Endocrinol 2012, 10.1038/nrendo.2012.48.
52. Lindsay R. Prevention and treatment of osteoporosis with ovarian hormones. Ann Chir Gynaecol 1988, 77(5-6):219-223.
53. Walker M.D., Novotny R., Bilezikian J.P., et al. Race and diet interactions in the acquisition, maintenance, and loss of bone. J Nutr 2008, 138:1256S-1260S.
54. Biller B.M., Caughlin J.F., Sake V., et al. Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol 1991, 78:996-1001.
55. Rosen C.J., Kiblanski A. Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med 2009, 122(5):409-414.
56. Fazeli P.K., Bredella M.A., Freedman L., et al. Marrow fat and preadipocyte factor-1 levels decrease with recovery in women with anorexia nervosa. J Bone Miner Res 2012, 10.1002/jbmr.1640.
57. Bredella M.A., Fazeli P.K., Freedman L.M., et al. Young women with cold-activated brown adipose tissue have higher bone mineral density and lower pref-1 than women without brown adipose tissue: a study in women with anorexia nervosa, women recovered from anorexia nervosa, and normal-weight women. J Clin Endocrinol Metab 2012, 97(4):E584-E590.
58. Divasta A.D., Feldman H.A., Giancaterino C., et al. The effect of gonadal and adrenal steroid therapy on skeletal health in adolescents and young women with anorexia nervosa. Metabolism 2012, 61(7):1010-1020.
59. Rosen C., Karsenty G., MacDougald O. Foreword: interactions between bone and adipose tissue and metabolism. Bone 2012, 50(2):429.
60. Kawai M., Rosen C.J. Bone: adiposity and bone accrual-still an established paradigm?. Nat Rev Endocrinol 2010, 6(2):63-64.
61. Hofbauer L.C., Brueck C.C., Singh S.K., et al. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 2007, 22:1317-1328.
62. Inzerillo A.M., Epstein S. Osteoporosis and diabetes mellitus. Rev Endocr Metab Disord 2004, 5:261-268.
63. de Liefde I.I., van der Klift M., de Laet C.E., et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 2005, 16:1713-1720.
64. de Paula F.J., Horowitz M.C., Rosen C.J. Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab Res Rev 2010, 26(8):622-630. 10.1002/dmrr.1135.
65. Nicodemus K.K., Folsom A.R., Iowa Women's Health Study Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001, 24:1192-1197.
66. Rosen C.J., Motyl K.J. No bones about it: insulin modulates skeletal remodeling. Cell 2010, 142(2):198-200.
67. Kawai M., Rosen C.J. PPARγ: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol 2011, 6(11):629-636.
68. Rosen C.J. Revisiting the rosiglitazone story-lessons learned. N Engl J Med 2010, 363(9):803-806.
69. Bilezikian J.P. Bone strength in primary hyperparathyroidism. Osteoporos Int 2003, 14(Suppl 5):113-117.
70. Silverberg S.J., Shane E., de la C.L., et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989, 4(3):283-291.
71. Khosla S., Melton L.J., Wermers R.A., et al. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 1999, 14(10):1700-1707.
72. Silverberg S.J., Shane E., Jacobs T.P., et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999, 341:1249-1255.
73. Rubin M.R., Bilezikian J.P., McMahon D.J., et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15-years. J Clin Endocrinol Metab 2008, 93(9):3462-3470.
74. Silverberg S.J., Lewiecki E.M., Mosekilde L., et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94(2):351-365.
75. Lewiecki E.M. Management of skeletal health in asymptomatic primary hyperparathyroidism. J Clin Densitom 2010, 13(4):324-334.
76. Bilezikian J.P., Potts J.T., Fuleihan G.E., et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res 2002, 17:N2-N11.
77. Miller P.D., Bilezikian J.P. Bone densitometry in asymptomatic primary hyperparathyroidism. J Bone Miner Res 2002, 17(Suppl 2):N98-N102.
78. Bilezikian J.P., Silverberg S.J. Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol 2010, 54(2):106-109.
79. Eldeiry L.S., Ruan D.T., Brown E.M., et al. Primary hyperparathyroidism and FHH: relationships and clinical implications. Endocr Pract 2012, 9:1-19.
80. Pitts C.J., Kearns A.E. Update on medications with adverse skeletal effects. Mayo Clin Proc 2011, 86(4):338-343.
81. Kaunitz A.M., Grimes D.A. Removing the black-box warning for depot medroxyprogesterone acetate. Contraception 2011, 84(3):212-213.
82. ACOG Committee Opinion No. 415: depot medroxyprogesterone acetate and bone effects. Obstet Gynecol 2008, 112(3):727-730.
83. Meier C., Brauchli Y.B., Jick S.S., et al. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab 2010, 95(11):4909-4916.
84. Renner R.M., Edelman A.B., Kaunitz A.M. Depot medroxyprogesterone acetate contraceptive injections and skeletal health. Womens Health (Lond Engl) 2010, 6(3):339-342.
85. Kaunitz A.M., Miller P.D., Rice V.M., et al. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception 2006, 74(2):90-99.
86. McCloskey E. Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 2006, 42:1044-1051.
87. Eastell R., Hannon R.A., Cuzick J., et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial. J Bone Miner Res 2006, 21:1215-1223.
88. Perez E.A., Josse R.G., Pritchard K.I., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a comparison study to NCIC CTG MA.17. J Clin Oncol 2006, 24:3629-3635.
89. Brufsky A., Harker W.G., Beck J.T., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007, 25:829-836.
90. Markopoulos C., Tzoracoleftherakis E., Polychronis A., et al. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res 2010, 12:R24.
91. Hines S.L., Sloan J.A., Atherton P.J., et al. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast 2010, 19:92-96.
92. Van Poznak C., Hannon R.A., Mackey J.R., et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010, 28:967-975.
93. Ellis G.K., Bone H.G., Chlebowski R., et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 2009, 118:81-87.
94. Grisso J.A., Kelsey J.L., O'Brien L.A., et al. Risk factors for hip fracture in men. Hip Fracture Study Group. Am J Epidemiol 1997, 145:786-793.
95. Vestergaard P., Rejnmark L., Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006, 19:76-83.
96. Yu E.W., Blackwell T., Ensrud K.E., et al. Acid suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008, 83:251-259.
97. Yang Y.X., Lewis J.D., Epstein S., et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296:2947-2953.